Get started
Author

Yinan Yu

Observed name: Y. Yu
ORCID: 0000-0001-7984-6970
Observed ORCID: 0000-0001-7984-6970
OpenAlex ID: A5049966746
132P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC): RATIONALE-307 updated analysis
2022 · J. Wang, S. Lu, et al. · Immuno-Oncology Technology · 5
PDF
138P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC): RATIONALE-304 updated analysis
2022 · S. Lu, J. Wang, et al. · Immuno-Oncology Technology · 3
Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer
2023 · Yinan Yu, Jianguo Zhao, et al. · Current Treatment Options in Oncology · 1
Author response for "The Role of Small extracellular vesicles in Tumor Development and the Prospect of Targeted Therapy"
2025 · Yinan Yu, Shengjie Wang, et al. · Publons reviews and discussion
The Role of Small Extracellular Vesicles in Tumor Development and the Prospect of Targeted Therapy
2025 · Yinan Yu, Shengjie Wang, et al. · Traffic
Author response for "The Role of Small extracellular vesicles in Tumor Development and the Prospect of Targeted Therapy"
2025 · Yinan Yu, Shengjie Wang, et al. · Publons reviews and discussion
Works count: 6
Citation count: 9
H-index: 2
I10-index:
Year
Topic
Type